Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-722-20), b)100mL (NDC 68180-722-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA
Published January 16, 2019 · Recall initiated: January 2, 2019
Summary
FDA records drug Class II recall D-0375-2019, published January 16, 2019 and initiated January 2, 2019. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 287,784 bottles; Lot: a) Lot #: F700329, F700330, F700328, Exp. January 2019; F700544, F700545, F700668, F700669, F700670, Exp. March 2019; F700958, Exp. April 2019 b) Lot #: F700327, F700392, F700393, Exp. January 2019; F700546, F700547, F700664, Exp. March 2019; F700967, Exp. April 2019, F701106, F701107, F701108, F701109, Exp. May 2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.
What to do
Voluntary: Firm initiated · Letter
Get an email if CEFDINIR has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- CEFDINIR
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Distributor
- Nationwide within the United States
- UPC
- 0368180723042
- Lot
- a) Lot #: F700329, F700330, F700328, Exp. January 2019; F700544, F700545, F700668, F700669, F700670, Exp. March 2019; F700958, Exp. April 2019 b) Lot #: F700327, F700392, F700393, Exp. January 2019; F700546, F700547, F700664, Exp. March 2019; F700967, Exp. April 2019, F701106, F701107, F701108, F701109, Exp. May 2019.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACefdinir for Oral Suspension USP, 250 mg/5 mL, packaged in a 60 mL bottle, Rx only, Manufactured for: LupinJune 5, 2024
- FDACefdinir for Oral Suspension USP 125 mg/5 mL (60 mL when reconstituted), 60 mL bottle, Rx only, ManufacturedMay 22, 2024
- FDACefdinir for Oral Suspension USP 250 mg/5 mL (60 mL when reconstituted), 60 mL bottle, Rx only, ManufacturedMay 22, 2024
- FDACefdinir for Oral Suspension USP, 250 mg/5mL, packaged in 60 mL bottles, Rx only, Manufactured for: LupinJuly 29, 2020
- FDAVecuronium Bromide for Injection 10 mg*, *1mg/mL when reconstituted to 10 mL Lyophilized, 10 x 10 mg vials, RxJanuary 16, 2019
- FDACefdinir for Oral Suspension USP, 250mg/5mL, packaged in a) 60mL (NDC 68180-723-20), b)100mL (NDCJanuary 16, 2019
Questions about this recall
Was Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-722-20), b)100mL (NDC 68180-722-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA recalled?
Yes. FDA published recall D-0375-2019 on January 16, 2019. Reported hazard: CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: CEFDINIR. UPC: 0368180723042.